Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Minolira Generic Name & Formulations
Legal Class
Rx
General Description
Minocycline HCl 105mg, 135mg; ext-rel tabs; scored.
Pharmacological Class
Tetracycline antibiotic.
How Supplied
Ext-rel tabs—30
Manufacturer
Generic Availability
NO
Minolira Indications
Indications
Inflammatory lesions of non-nodular moderate to severe acne vulgaris.
Minolira Dosage and Administration
Adult
Swallow whole. Give approximately 1mg/kg once daily for 12wks. Weight-based dosing (45–59kg): 52.5mg; (60–89kg): 67.5mg; (90–125kg): 105mg; (126–136kg): 135mg. Renal impairment: reduce dose or extend dosing intervals.
Children
<12yrs: not established.
Minolira Contraindications
Not Applicable
Minolira Boxed Warnings
Not Applicable
Minolira Warnings/Precautions
Warnings/Precautions
Monitor blood, renal, and hepatic function periodically. Discontinue if skin erythema, DRESS syndrome, or superinfection develops. Overweight women. History of intracranial hypertension. Monitor for visual disturbances. Renal or hepatic impairment. Avoid sun or UV light. Pregnancy, nursing mothers: not recommended.
Minolira Pharmacokinetics
See Literature
Minolira Interactions
Interactions
Avoid concomitant penicillins, isotretinoin. Fatal renal toxicity with concomitant methoxyflurane. May need to reduce concomitant anticoagulant dose. Absorption reduced by antacids containing aluminum, calcium, magnesium and iron. May antagonize oral contraceptives. May interfere with fluorescence test.
Minolira Adverse Reactions
Adverse Reactions
Headache, fatigue, dizziness, pruritus, malaise; teeth discoloration, delayed skeletal development, intracranial hypertension, CNS effects, C.difficile-associated diarrhea, photosensitivity, increased BUN, hepatotoxicity, renal toxicity, hyperpigmentation, skin/hypersensitivity reactions (may be severe), lupus-like syndrome, serum sickness-like syndrome.
Minolira Clinical Trials
See Literature
Minolira Note
Not Applicable
Minolira Patient Counseling
See Literature
